Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid Leukemia.

IF 1.8 4区 医学 Q3 ONCOLOGY
Muhammad Hamza Gul, Aisha Rehman Siddiqui, Farwa Zehra, Malaika Rehmani, Faraz Waheed, Natasha Masood, Maleeha Saqib, Mahnoor Keen, Sharan Siddharth Keshetty, Maham Maqsood, Siddharth Arjun Atwal, Muhammad Hamza Sikandari, Abdul Baseer Wardak
{"title":"Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid Leukemia.","authors":"Muhammad Hamza Gul, Aisha Rehman Siddiqui, Farwa Zehra, Malaika Rehmani, Faraz Waheed, Natasha Masood, Maleeha Saqib, Mahnoor Keen, Sharan Siddharth Keshetty, Maham Maqsood, Siddharth Arjun Atwal, Muhammad Hamza Sikandari, Abdul Baseer Wardak","doi":"10.46883/2024.25921025","DOIUrl":null,"url":null,"abstract":"<p><p>Acute myeloid leukemia (AML) is a heterogeneous disease characterized by the accumulation of malignant myeloid progenitor hematopoietic cells in the bone marrow and peripheral blood. Recent studies have shown promising results with the use of small molecule inhibitors and targeted therapy in the treatment of patients with AML. One such molecule is venetoclax, which has been approved in AML by the FDA in combination with hypomethylating agents or low-dose cytarabine. We thoroughly searched electronic literature related to venetoclax and its role in AML, using databases such as MEDLINE, PubMed, Google Scholar, and PsychInfo, through April 2024. We applied population, intervention, comparison, and outcome criteria, specifically focusing on studies with a population using venetoclax from review articles and clinical trials. All selected studies were required to be in English, and any study that did not involve the use of venetoclax was excluded. A meticulous literature review was conducted to consolidate the current knowledge and new combination therapies on AML. In our review article, we focused on the latest advances in the treatment of patients with AML. Based on the literature, we recommend that physicians prioritize the use of venetoclax in the management of this deadly disease because it has been shown to significantly impact the course of the disease.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology-New York","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.46883/2024.25921025","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Acute myeloid leukemia (AML) is a heterogeneous disease characterized by the accumulation of malignant myeloid progenitor hematopoietic cells in the bone marrow and peripheral blood. Recent studies have shown promising results with the use of small molecule inhibitors and targeted therapy in the treatment of patients with AML. One such molecule is venetoclax, which has been approved in AML by the FDA in combination with hypomethylating agents or low-dose cytarabine. We thoroughly searched electronic literature related to venetoclax and its role in AML, using databases such as MEDLINE, PubMed, Google Scholar, and PsychInfo, through April 2024. We applied population, intervention, comparison, and outcome criteria, specifically focusing on studies with a population using venetoclax from review articles and clinical trials. All selected studies were required to be in English, and any study that did not involve the use of venetoclax was excluded. A meticulous literature review was conducted to consolidate the current knowledge and new combination therapies on AML. In our review article, we focused on the latest advances in the treatment of patients with AML. Based on the literature, we recommend that physicians prioritize the use of venetoclax in the management of this deadly disease because it has been shown to significantly impact the course of the disease.

范式转变的导航 Venetoclax 治疗重新定义了急性髓性白血病的前景。
急性髓性白血病(AML)是一种以骨髓和外周血中恶性髓系祖细胞造血细胞聚集为特征的异质性疾病。最近的研究显示,使用小分子抑制剂和靶向疗法治疗急性髓细胞白血病患者取得了可喜的成果。venetoclax就是这样一种分子,FDA已批准将其与低甲基化药物或小剂量阿糖胞苷联合用于急性髓细胞性白血病的治疗。我们使用 MEDLINE、PubMed、Google Scholar 和 PsychInfo 等数据库全面检索了与 Venetoclax 及其在急性髓细胞性白血病中的作用相关的电子文献,检索期至 2024 年 4 月。我们采用了人群、干预、比较和结果标准,特别关注综述文章和临床试验中使用 venetoclax 的人群的研究。所有被选中的研究都必须是英文研究,任何不涉及使用 venetoclax 的研究都被排除在外。我们进行了细致的文献综述,以整合当前关于急性髓细胞性白血病的知识和新的联合疗法。在综述文章中,我们重点介绍了治疗急性髓细胞性白血病患者的最新进展。根据文献,我们建议医生在治疗这种致命疾病时优先使用 Venetoclax,因为它已被证明能显著影响病程。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Oncology-New York
Oncology-New York 肿瘤学-肿瘤学
CiteScore
1.60
自引率
0.00%
发文量
69
审稿时长
6-12 weeks
期刊介绍: Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信